Your browser doesn't support javascript.
loading
Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65 Years and Older.
Shiragami, Makoto; Mizukami, Akiko; Kaise, Toshihiko; Curran, Desmond; Van Oorschot, Desiree; Bracke, Benjamin; Watanabe, Daisuke.
Affiliation
  • Shiragami M; Faculty of Pharmaceutical Sciences, Teikyo Heisei University, Tokyo, Japan.
  • Mizukami A; Healthoutcomes Department, GSK, Tokyo, Japan. akiko.mizukami@gsk.com.
  • Kaise T; Healthoutcomes Department, GSK, Tokyo, Japan.
  • Curran D; Value Evidence Department, GSK, Wavre, Belgium.
  • Van Oorschot D; Value Evidence Department, GSK, Wavre, Belgium.
  • Bracke B; Value Evidence Department, GSK, Wavre, Belgium.
  • Watanabe D; Department of Dermatology, Aichi Medical University, Aichi, Japan.
Dermatol Ther (Heidelb) ; 9(2): 281-297, 2019 Jun.
Article in En | MEDLINE | ID: mdl-30929219
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Language: En Journal: Dermatol Ther (Heidelb) Year: 2019 Document type: Article Affiliation country: Japan Country of publication: Switzerland
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Language: En Journal: Dermatol Ther (Heidelb) Year: 2019 Document type: Article Affiliation country: Japan Country of publication: Switzerland